![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Miltenyi will develop and manufacture Cell BioEngines' expanded hematopoietic stem cell transplantation (HSCT) product, CBE-101, for clinical use in hematology-oncology.
Lead Product(s): CBE-101
Therapeutic Area: Oncology Product Name: CBE-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cell BioEngines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 29, 2023
Details:
Under the agreement, Syena will support the development of a GMP-compliant T-cell receptor (TCR) natural killer (NK) cell therapy, SY-001, targeting the tumor-associated neoantigen, PRAME.
Lead Product(s): SY-001
Therapeutic Area: Oncology Product Name: SY-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syena
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2023